Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms

Billany, Roseanne E; Selvaskandan, Haresh; Adenwalla, Sherna; Hull, Katherine L.; March, Daniel S.; Burton, James O.; Bishop, Nicolette C.; Carr, Edward J; Beale, Rupert; Tang, Julian W.; Bird, Paul; C, Holmes; Baines, Richard; Brunskill, Nigel J.; Graham-Brown, Matthew P M

doi:10.1016/j.kint.2021.04.008

Cited by 56 publications

(57 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regards to factors for a poor antibody response other than older age, Longlune et al found that receiving immunosuppressants was an independent factor for antibody unresponsiveness one month following BNT162b2 vaccination in chronic dialysis patients [ 53 ]. Several other studies have also reported similar findings [ 47 , 50 , 54 ]. Lacson et al further observed that non-responders after two doses of BNT162b2 or mRNA-1273 were more like to be female, have a shorter dialysis vintage, have received other vaccines, to be hospitalized within 14 days, and have congestive heart failure [ 54 ].…”

Section: Effectiveness Of Covid-19 Vaccines In Hemodialysis Patientssupporting

confidence: 82%

“…Billany et al conducted an experiment of 94 patients with MHD and evaluated antibodies to S1 spike protein against COVID-19 28 days following a single dose of BNT162b2 or AZD1222. Their results showed that previous COVID-19 infection was an indicator of antibody detection [ 47 ]. Attias et al studied the serial responses of anti-spike 1 IgG antibody following BNT162b2 vaccination in 69 patients with MHD.…”

Section: Effectiveness Of Covid-19 Vaccines In Hemodialysis Patientsmentioning

confidence: 99%

“…Different characters of patients, vaccine type and dosage, definitions of the humoral response, and timepoints of antibody detection may contribute to the variable results across the studies. BNT162b2 was shown to be effective in most previous studies, although the antibody response remained diverse among different vaccines [ 47 , 52 , 54 ]. Current studies have mostly evaluated the effectiveness of vaccines in the form of IgG titers.…”

Section: Effectiveness Of Covid-19 Vaccines In Hemodialysis Patientsmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 Vaccines in Patients with Maintenance Hemodialysis

Yen

Lin

Chen

et al. 2021

JPM

View full text Add to dashboard Cite

The COVID-19 pandemic has infected more than 180 million people and caused more than 3.95 million deaths worldwide. In addition to personal hygiene, augmented cleaning, social distancing, and isolation, vaccine development and immunization are essential for this highly contagious disease. Patients with maintenance hemodialysis (MHD) have a greater risk of COVID-19 infection owing to their comorbidities, defective immunity, and repeated crowded in-center dialysis settings. However, many patients hesitate to get vaccinated because of their misunderstandings. The Efficacy of COVID-19 vaccination has been intensively discussed in the general population, whereas the data concerning the effectiveness of vaccination in MHD patients are relatively scanty. Nevertheless, those limited publications can provide some valuable information. Overall, lower and more delayed antibody responses following COVID-19 vaccination were observed in patients with MHD than in healthy controls in the settings of different populations, vaccines and dosage, definitions of the immune response, and antibody detection timepoints. Younger age, previous COVID-19 infection, and higher serum albumin level were positively associated with antibody formation, whereas older age and receiving immunosuppressive therapy were unfavorable factors. However, it remains uncertain between the elicited antibodies following vaccination and the genuine protection against COVID-19 infection. Patients with MHD should make their COVID-19 vaccination a priority in addition to other protective measures. More studies focusing on different vaccines, non-humoral immune responses, and risk-benefit analyses are warranted.

show abstract

Section: Effectiveness Of Covid-19 Vaccines In Hemodialysis Patientssupporting

confidence: 82%

Section: Effectiveness Of Covid-19 Vaccines In Hemodialysis Patientsmentioning

confidence: 99%

Section: Effectiveness Of Covid-19 Vaccines In Hemodialysis Patientsmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Vaccines in Patients with Maintenance Hemodialysis

Yen

Lin

Chen

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…Emerging data on the humoral response of other hemodialysis cohorts have shown similar seroconversion results ranging from 82 to 96%. All but the Frantzen et al study (244 patients) 30 had a smaller number of participants than ours 21,22,[31][32][33][34] . Moreover, to our knowledge ours is the largest hemodialysis cohort to have evaluated the immune response to the mRNA-1273 vaccine 22 .…”

Section: Discussionmentioning

confidence: 52%

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients

Broseta

Rodríguez-Espinosa

Rodríguez³

et al. 2021

American Journal of Kidney Diseases

109

106

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…Several studies reported variable humoral and cellular responses to different platforms of the approved SARS-CoV-2 vaccine in chronic dialysis patients. 3 , 4 , 5 , 6 , 7 The preliminary studies revealed that most ESKD patients receiving maintenance dialysis developed decent seroconversion after the second vaccine dose. However, most immunogenicity and safety data against SARS-CoV-2 in these susceptible individuals mainly derived from the mRNA or adenoviral-vectored vaccines.…”

mentioning

confidence: 99%